IART
$49.61
Integra Lifesciences
$.78
1.60%
IART
Earnings Whisper ®
N/A
4th Quarter December 2017
Consensus:  $0.56
Revenue:  $361.17 Mil
Thursday
Jan 25
6:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Guidance announcement made Thursday, October 26, 2017

What do you expect when IART reports earnings?
Beat
Meet
Miss

Where is IART's stock price going from here?
Up
Flat
Down
Stock chart of IART
Analysts
Summary of analysts' recommendations for IART
Score
Grade
Pivots
Resistance
$50.30
$49.78
$49.30

$48.78

Support
$48.30
$47.78
$47.30
Tweet
Growth
Description
Integra LifeSciences Corp. develops, manufactures and markets medical devices, implants and biomaterials primarily used in the treatment of burns and skin defects, spinal and cranial disorders, orthopedics and other surgical applications. Integra seeks to be the world's leading company specializing in implantable medical and biopharmaceutical therapies to target and control cell behavior, and to build shareholder value by acquiring, discovering, and developing cost-effective, off-the-shelf products that satisfy unmet medical needs.
Peers
Abbott LaboratoriesBoston ScientificStrykerBecton, DickinsonC. R. BardBaxter InternationalWaters3MResMedAbiomed